Aethlon Medical Releases Dengue Treatment Data.

In Preliminary Studies, New Medical Technology Removes More Than 99% of Dengue Virus

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that researchers at the National Institute of Virology (NIV) in India have documented that the Aethlon Hemopurifier[R] is highly efficient in capturing infectious dengue virus. In preliminary studies, the Aethlon Hemopurifier[R] removed 99.6% of live dengue virus from fluids in 30 minutes. The NIV is the Government of India's leading infectious disease research center and a collaborating laboratory of the World Health Organization (WHO). "The data resulting from the NIV study exceeds expectations," stated Aethlon Chairman and CEO, James A. Joyce. "We will continue to initiate programs that support the commercialization of the Hemopurifier[R] as a potential treatment for dengue and other viral threats resistant to drug and vaccine therapy."

At present, there is no antiviral drug or vaccine therapy to treat dengue. The global prevalence of dengue and dengue hemorrhagic fever (DHF), the more severe and often fatal form of the disease, has increased dramatically in recent decades. The disease is now endemic in more than 100 countries in Africa, the Americas, Southeast Asia and the western Pacific, according to the World Health Organization. With one-third of the world's population at risk, there are an estimated 50 million to 100 million cases of dengue infection and 500,000 cases of DHF worldwide every year.

The Hemopurifier[R] is a therapeutic device designed to mimic the natural immune response of clearing viruses and related toxins before the occurrence of cell and organ infection. Aethlon has previously demonstrated the Hemopurifier[R] is able to capture a broad-spectrum of drug and vaccine resistant viruses, including HIV, Hepatitis-C (HCV), and certain pathogens considered high-priority bioterror threats. The Company has also conducted a successful 24-treatment safety study in health compromised dialysis patients co-infected with HCV. The data derived from previous Hemopurifier[R] studies was measured by real time polymerase chain reaction (RT-PCR), a technique that documents total virus capture, including the removal of non-infectious virus and viral fragments. However, often less than 1% of Dengue, HIV, HCV, and other RNA viruses are infectious and able to proliferate within humans.

In the NIV study, researchers utilized a diagnostic procedure that measured plaque-forming units (PFU), to determine the ability of the Hemopurifier[R] to capture only the live infectious forms of dengue that cause disease progression. When researchers circulated 5 ml of cultured dengue virus solution with a concentration of 28 billion virus copies per ml (as measured by RT-PCR) of both live infectious and non-infectious virus through a small scale Hemopurifier[R], live virus was captured at a significantly greater rate than non-infectious virus. The Hemopurifier[R] removed 99.6% of the live virus from culture fluids in 30 minutes. In contrast, 33% of total virus, including both infectious and non-infectious forms, was removed in the same time period. Similarly, after one hour of recirculation, 99.7% of the live virus had been removed vs. 54% of total virus.

Based on these data points, it appears the Hemopurifier[R] has a selective affinity to capture infectious virus at a rate up to 170-180 times faster than non-infectious virus. As a result, Aethlon has evidence indicating the Hemopurifier[R] is significantly more effective in capturing infectious virus than previously anticipated. The ability to rapidly clear circulating live virus inhibits the spread of the infection, thus improving the environment for the natural immune response to defeat an infectious viral pathogen before it becomes life threatening.

As a result of this new discovery, Aethlon has filed a new patent with The United States Patent and Trademark Office (USPTO) entitled: "DEVICE AND METHOD FOR PURIFYING VIRALLY INFECTED BLOOD"

About Aethlon Medical

Aethlon Medical has developed a first-in-class medical device to assist in the treatment of infectious disease. The device, known as the Hemopurifier[R], is a platform technology positioned to be a broad-spectrum treatment for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon has recently submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to initiate human safety studies of the Aethlon Hemopurifier([R])as a treatment countermeasure against select category "A" bioterror threats. Additional studies to demonstrate utility of the Hemopurifier([R])as a countermeasure against bioterror threats are being conducted with researchers at The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Category "A" bioterror threats are defined by the CDC as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; may cause public panic and social disruption, and require special action for public health preparedness. Global researcher, Frost & Sullivan awarded the Hemopurifier([R]) the 2006 Technology Innovation Award, and The AIDS Institute presented Aethlon with the 2007 Innovative HIV Life Sciences Leadership Award. The Company has also initiated research on a second generation Hemopurifier([R]) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.